Supplemental approval from the FDA for Jylamvo (methotrexate) to treat ALL and polyarticular juvenile idiopathic arthritis – Shorla Oncology
Shorla Oncology , a U.S.-Ireland specialty pharmaceutical company, announced that the FDA has expanded the approval of Jylamvo (methotrexate) to include the treatment of pediatric patients with acute… read more.
